Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8199178rdf:typepubmed:Citationlld:pubmed
pubmed-article:8199178lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:8199178lifeskim:mentionsumls-concept:C2003888lld:lifeskim
pubmed-article:8199178lifeskim:mentionsumls-concept:C0023824lld:lifeskim
pubmed-article:8199178lifeskim:mentionsumls-concept:C0001721lld:lifeskim
pubmed-article:8199178lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:8199178pubmed:issue6lld:pubmed
pubmed-article:8199178pubmed:dateCreated1994-7-7lld:pubmed
pubmed-article:8199178pubmed:abstractTextThe National Cholesterol Education Program (NCEP) recommends that dietary total fat, saturated fat, and cholesterol intake be reduced to < or = 30% of calories, < 10% of calories, and < 300 mg/d, respectively (step 1 diet), in the general population to reduce plasma low-density lipoprotein cholesterol (LDL-C) levels and heart disease risk. We examined the LDL-C-lowering response to such a diet (26% fat, 8% saturated fat, and 201 mg/d cholesterol) compared with an average American diet (39% fat, 15% saturated fat, and 435 mg cholesterol/d) in 153 subjects using diet periods of 4 through 24 weeks for each diet phase. The mean LDL-C reduction was 13% in men (n = 93) and 7% in postmenopausal women (n = 60). The effect of apolipoprotein (apo) A-IV phenotype on responsiveness was examined. LDL-C lowering in men was significantly (P < .005) less (7%) for 17 apoA-IV (1/2) subjects than for 76 apoA-IV (1/1) subjects (16%). In women, 7% lowering was observed in both 12 apoA-IV (1/2) subjects and 48 apoA-IV (1/1) subjects. ApoA-IV phenotype had a significant effect on plasma high-density lipoprotein cholesterol levels during both dietary periods; women carrying the apoA-IV-2 allele had higher levels than those homozygous for the apoA-IV-1 allele. The opposite was true for triglyceride levels, but only during the period when the subjects consumed the high-fat, high-cholesterol diet.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:8199178pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:languageenglld:pubmed
pubmed-article:8199178pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:citationSubsetIMlld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8199178pubmed:statusMEDLINElld:pubmed
pubmed-article:8199178pubmed:monthJunlld:pubmed
pubmed-article:8199178pubmed:issn1049-8834lld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:PECKH DHDlld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:SchaeferE JEJlld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:JuddJ TJTlld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:OrdovasJ MJMlld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:LichtensteinA...lld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:Lopez-Miranda...lld:pubmed
pubmed-article:8199178pubmed:authorpubmed-author:ClevidenceBBlld:pubmed
pubmed-article:8199178pubmed:issnTypePrintlld:pubmed
pubmed-article:8199178pubmed:volume14lld:pubmed
pubmed-article:8199178pubmed:ownerNLMlld:pubmed
pubmed-article:8199178pubmed:authorsCompleteYlld:pubmed
pubmed-article:8199178pubmed:pagination884-91lld:pubmed
pubmed-article:8199178pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:meshHeadingpubmed-meshheading:8199178-...lld:pubmed
pubmed-article:8199178pubmed:year1994lld:pubmed
pubmed-article:8199178pubmed:articleTitleApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering.lld:pubmed
pubmed-article:8199178pubmed:affiliationLipid Metabolism Laboratory, USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111.lld:pubmed
pubmed-article:8199178pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8199178pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8199178pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:8199178pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8199178lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8199178lld:pubmed